President & Founder
With more than 20 years of global experience developing business in the pharmaceutical industry, Daisy Rivera-Muzzio serves as president and managing partner of Acumen Biopharma. Rivera-Muzzio is an expert in positioning scientific arguments regarding intellectual property involving innovator and generic companies in the healthcare industry. In addition to leading Acumen Biopharma, she continues to head DRM BioPharmSource, LLC, a consulting firm working with corporate leaders in the healthcare and life science industries to fuel growth initiatives and establish strategic partnerships. Rivera-Muzzio assists those seeking to develop innovative technologies in accelerating commercialization of intellectual property.
While former Director of Product Development at Schein Pharmaceuticals and an active participant in numerous industry and US Food and Drug Administration (FDA) forums, Rivera-Muzzio developed a life-long interest in new technologies and partnerships in emerging markets — especially generics.
Rivera-Muzzio is particularly adept at managing interactions with academia in areas of novel technology for drug delivery. Scientific arguments are her forte — especially when applied to generic products and addressing fundamental scientific questions.
Formerly the Senior Director of Product Licensing for the Established Products Business Unit at Pfizer, Inc., Rivera-Muzzio completed licensing and supply agreements in the generic business with combined projected net revenue of $700M.
Rivera-Muzzio is an expert in the evaluation and risk assessment of licensing generic formulations having conducted cross-functional analyses for licensing and acquisition of several major platform technologies. She also understands the power of effective business development, having created and developed partnership opportunities in pharmaceuticals (branded and unbranded generics), animal health and consumer healthcare products.
Rivera-Muzzio’s strong background and experience of pharmaceutical product manufacturing operations, quality assurance, regulatory requirements, process development and third-party supply operations management has been critical to her formation of Acumen BioPharma business. In addition to connecting clients to the right expert and identifying the best technology to address their needs Rivera-Muzzio is an industry thought leader on the market impact of the loss of intellectual property on pharmaceutical products.
Rivera-Muzzio holds a Bachelor of Science in Pharmacy and an MS in Industrial Pharmacy from the University of Puerto Rico. She earned her MBA from Massachusetts Institute of Technology in Cambridge, MA.
Mrs. Rivera-Muzzio is the co-Chair of the NJ Chapter of Licensing Executive Society (LES), VP of Programs for the MIT Alumni NNJ Chapter, active member of the MIT Educational Council of Princeton, NJ and of the Healthcare Businesswomen Association (HBA).
For nearly 25 years, Professor Fernando Muzzio has focused on pharmaceutical product and process design. A Distinguished professor at Rutgers University, he has developed sought-after expertise in both academia and business, which uniquely positions him as a source of unparalleled research information and testimony supporting resolution of scientific questions involving pharmaceutical foundations and intellectual property (IP).
Dr. Muzzio also directs the National Science Foundation Engineering Research Center on Structured Organic Particulate Systems with a special emphasis on continuous manufacturing, particle engineering and personalized medicine. In this capacity, Muzzio directs research involving the US Food and Drug Administration (FDA) and more than 50 global companies including world-class technology suppliers in equipment, instrumentation, software, and control industries. In his capacity as center director, Dr. Muzzio is a recognized thought leader regarding the design and implementation of continuous manufacturing systems, which has been characterized by the FDA as one of the most important manufacturing megatrends of the 21st century.
Dr. Muzzio maintains consulting relationships with numerous other firms, including 15 of the top 25 pharmaceutical manufacturing companies in both the branded and generic sectors in the use of statistical methodologies to support product and process optimization and regulatory compliance. He heads a network that provides unmatched academic resources in establishing facts and supporting data regarding pharmaceutical particle technology.
The author of more than 230 peer-reviewed scientific articles and numerous patents and book chapters, Dr. Muzzio was appointed a voting member of the FDA Committee on Pharmaceutical Sciences and Clinical Pharmacology in 2010, where he currently serves as a consulting member.
Dr. Muzzio is a renowned resource for providing understandable and effective expert testimony in many aspects of pharmaceutical product and process development. He leads one of the strongest teams in academia for providing resources supporting and establishing resolution of scientific questions involving pharmaceutical particle technology.
Dr. Muzzio is also a recognized expert in innovative materials and product testing, having developed and implemented numerous methodologies for the testing and statistical analysis of powder blending, sampling, content uniformity, powder wettability, electrostatics, tablet microstructure, cascade impactors, tablet dissolution and coating, and process characterization. He is also recognized as a global leader in pharmaceutical nanotechnology, having led NIH/NSF doctoral training program in Nanopharmaceutical Engineering.
Muzzio holds a BS in Chemical Engineering from Universidad de Mar del Plata (Argentina) and a PhD in Chemical Engineering from the University of Massachusetts – Amherst.